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The incidence of Clostridium difficile infection is increasing worldwide, and its severity and resulting mortality are also on the 
rise. Metronidazole and oral vancomycin remain the treatments of choice, but there are concerns about treatment failure and 
the appearance of resistant strains. Furthermore, antibiotic therapy results in recurrence rates of at least 20%. Fecal transplan-
tation may be a feasible treatment option for recurrent C. difficile infection; moreover, it may be an early treatment option for 
severe C. difficile infection. We report a case of severe C. difficile infection treated with fecal transplantation using a nasoenteric 
tube during an initial episode. This is the first reported case of fecal transplantation using a nasoenteric tube during an initial 
episode of C. difficile infection in Korea.
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Introduction
The incidence, severity, and resulting mortality of Clostridi-
um difficile infection are increasing worldwide [1-3]. In spite 
of the considerable increase in the incidence and severity of C. 
difficile infection, metronidazole and oral vancomycin remain 
the treatments of choice [4]. Metronidazole is generally used 
for mild and moderate C. difficile infection, but treatment fail-
ure is a growing problem. Vancomycin is costly, and there is 
concern about the appearance of resistant strains [5]. Further-
more, antibiotic therapy has recurrence rates of at least 20%, 
which increase with each subsequent C. difficile infection [6]. 
Els van Nood et al. reported that in patients with recurrent C. 
difficile infection, fecal transplantation resulted in better treat-
ment outcomes compared with conventional antibiotic treat-
ment. Fecal transplantation had a cure rate of 81.3% following 
a single nasoenteric infusion and 93.8% following a second in-
fusion, while standard vancomycin therapy with or without 
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bowel lavage had a 23.1-30.8% cure rate [7]. Fecal transplanta-
tion may be a treatment option for recurrent C. difficile infec-
tion; moreover, it may be an early treatment option for severe 
C. difficile infection [8]. In Korea, two cases of severe refracto-
ry C. difficile infection treated with fecal transplantation 
during an initial episode have been reported. One case used 
esophagogastroduodenoscopy (EGD) while the other case 
used enema [9, 10]. Here, we report the first case of severe ini-
tial C. difficile infection, refractory to antibiotics, that was 
treated with fecal transplantation using a nasoenteric tube in 
Korea.
Case Report
A 65-year-old man visited the emergency room with a 3-day 
history of bilateral leg weakness and fever. His blood pressure 
was 86/43 mmHg, and his body temperature was 39.3°C at 
presentation. He had a history of hypertension and recent sur-
gery for lumbar spinal stenosis three months before admis-
sion. Initial peripheral blood count showed a white blood cell 
count of 4,710/mm3 (neutrophils, 92.2%; lymphocytes, 5.2%; 
monocytes, 1.4%), hemoglobin level of 11.3 g/dL and platelet 
count of 137,000/mm3. Prothrombin time (PT) and activated 
partial thromboplastin time (aPTT) were 13.2 sec and 34.8 sec, 
respectively, and C-reactive protein level was 286.06 mg/L. 
Blood chemistry showed a total protein level of 5.1 g/dL, albu-
min level of 2.9 g/dL, total bilirubin level of 0.5 mg/dL, aspar-
tate aminotransferase/alanine aminotransferase 27/17 IU/L, 
BUN/Cr 56.6/2.42 mg/dL, Na/K 138/4.1 mEq/L and Ca/P 
7.6/2.7 mg/dL. Lumbar magnetic resonance imaging (MRI) 
was performed and revealed infective spondylitis and multi-
ple paraspinal abscesses. The patient received empiric intra-
venous antibiotic treatment with 2.0 g ceftriaxone every 24 
hours and 200 mg teicoplanin every 24 hours after peripheral 
blood culture and urine culture. He underwent incision and 
drainage of multiple abscesses. Streptococcus intermedius 
was identified in all three initial blood cultures, and the mini-
mal inhibitory concentration (MIC) for penicillin G was 0.016 
µg/mL. Antibiotics were changed to 4 million units penicillin 
G every 4 hours. On the 35th hospital day, he had urinary tract 
infection and bacteremia from an extended-spectrum be-
ta-lactamase (ESBL) organism and was treated with 500 mg 
imipenem every 6 hours.
On the 59th hospital day, during conservative treatment for 
infective spondylitis, the patient developed a fever of 38.1°C 
and diarrhea; his blood pressure was 89/58 mmHg. Due to 
suspicion of C. difficile infection, oral 500 mg metronidazole 
was given every 8 hours empirically. Stool C. difficile toxin A/B 
and culture were confirmed to be positive. On the 60th hospi-
tal day, laboratory results revealed a white blood cell count of 
39,560/mm3 (neutrophils, 89.4%; lymphocytes, 6.2%; mono-
cytes, 2.8%), hemoglobin level of 11.8 g/dL, platelet count of 
292,000/mm3, BUN/Cr of 18.0/0.65 mg/dL, and albumin level 
of 1.8 g/dL. On the 61st hospital day, oral metronidazole was 
switched to 250 mg oral vancomycin every 6 hours due to in-
creased severity of diarrhea and the detection of paralytic ile-
us on abdominal X-ray despite administration of oral metroni-
dazole. Intravenous metronidazole (every 8 hours) and 
vancomycin enema 500 mg (every 6 hours) were also added 
to the treatment course. Unfortunately, symptoms did not im-
prove, and disseminated intravascular coagulation (DIC) pro-
gressed although leukocytosis was improved. On the 74th 
hospital day, laboratory results showed a white blood cell 
Figure 1. Method of fecal transplantation. (A) The tip of the nasoenteric tube was placed at the third portion of the duodenum by esophagogastroduode-
noscopy. (B, C) Fifty grams stool collected from the donor was diluted with 500 mL normal saline, and the supernatant was filtered out with gauze. This 
solution was placed into the feeding bag and infused through a nasoenteric tube for 30 minutes.
A B C
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count of 3,240/mm3 (neutrophils, 71.0%; lymphocytes, 20.1%; 
monocytes, 6.8%), a hemoglobin level of 7.8 g/dL, platelet 
count of 67,000/mm3, PT/aPTT of 22.6 sec/65.4 sec, albumin 
level of 1.9 g/dL and C-reactive protein level of 77.2 mg/L. Fe-
cal transplantation was recommended and the patient con-
sented to the procedure. The patient’s wife, who had no rele-
vant medical history and no symptoms of acute disease, was 
selected as the donor. On the 75th hospital day, fecal trans-
plantation was performed. The tip of a nasoenteric tube was 
placed in the third portion of the duodenum by EGD. Fifty 
grams of stool collected from the donor was diluted with 500 
mL normal saline and the supernatant was filtered out with 
gauze. This solution was placed into the feeding bag and in-
fused through a nasoenteric tube for 30 minutes (Fig. 1). 
After fecal transplantation, diarrhea and ileus gradually im-
proved and fever subsided. Platelet count, PT/aPTT and albu-
min level were also improved (Fig. 2). On the 84th hospital 
day, 9 days after fecal transplantation, laboratory test results 
were as follows: white blood cell count 6,280/mm3 (neutro-
phils, 65.3%; lymphocytes, 24.2%; monocytes, 5.3%), hemoglo-
bin 8.1 g/dL, platelets 224,000/mm3, PT/aPTT 14.8 sec/34.4 
sec and albumin 2.7 g/dL. The patient’s diet was slowly ad-
vanced, and oral vancomycin was tapered to 125 mg every 12 
hours. On the 94th hospital day, the patient was discharged 
with oral vancomycin after his symptoms had resolved. When 
he visited outpatient clinic 12 days after discharge, he had no 
symptoms of PMC; therefore, oral vancomycin was discontin-
ued.
Discussion
The destruction of normal intestinal flora after antibiotic use 
is the likely cause of most C. difficile infections. Stool trans-
plantation may replace the lost flora with bacteria collected 
from healthy donors. Reestablishment of normal gut flora 
makes fecal transplant a logical treatment option for C. diffi-
cile infection [6]. Els van Nood et al. reported that the de-
creased microbial diversity of infected patients recovered to 
the level of the donors after fecal transplantation [7].
In current clinical practice, fecal transplantation is indicated 
for recurrent C. difficile infection and severe infection with no 
response to standard antibiotic therapy [11]. The efficacy of 
fecal transplantation in recurrent C. difficile infection has 
been established in many case reports and meta-analyses and 
one recent randomized controlled study [12]. There is a lack of 
data supporting fecal transplantation use in severe or fulmi-
nant C. difficile infection, but emerging data indicate that fecal 
transplantation is also effective in such cases [8]. One recent 
retrospective study reported the effectiveness of fecal trans-
plantation in 14 patients with severe, refractory C. difficile in-
fection. Patients were categorized as having severe C. difficile 
infection if they met two or more of the following criteria: age 
Table 1. Cases of fecal transplantation in Korea 
Author
(year)
Indication Sex Age
Donor  
relationship
Infusion route Infusion volume Outcome
Adverse
events
Gweon et al. 
2013 [9]
Refractory
CDI
Male 83 Wife EGD Stool 150 g 
Normal saline 300 mL
CDI resolved None
Recurrent
CDI
Male 86 Daughter EGD Stool 100 g
Normal saline 300 mL
CDI resolved Vomiting
Moon et al. 
2013 [10]
Recurrent
CDI
Male 83 Daughter Enema Stool 50 mL
Normal saline 200 mL
CDI resolved Mild diarrhea
Refractory
CDI
Female 70 Son Enema Stool 50 mL
Normal saline 300 mL
CDI resolved None
This case Refractory
CDI
Male 65 Wife Nasoenteric tube Stool 50 g
Normal saline 500 mL
CDI resolved None
CDI, Clostridium difficile infection; EGD, esophagogastroduodenoscopy.
Figure 2. Serum albumin level and platelet count during treatment.
HOD, hospital day.
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> 60 years, serum albumin < 2.5mg/dL, body temperature > 
38.3°C, or a white blood cell count > 15,000/mm3 within 48 
hours of diagnosis; or if they met one of the following criteria: 
endoscopic evidence of pseudomembranous colitis or treat-
ment in the intensive care unit for C. difficile infection. Refrac-
tory infection was defined as non-resolution of C. difficile in-
fection despite 7 days of therapy with oral vancomycin. The 
cure rate was 79% (11 of 14). This study included six patients 
with initial episodes of C. difficile infection [13]. Because of its 
cost effectiveness, high cure rate, minimal risk and reestab-
lishment of normal flora, fecal transplantation has even been 
proposed as the initial treatment modality for severe C. diffi-
cile infection [14].
In Korea, four cases of fecal transplantation have been re-
ported (Table 1). Two cases were recurrent C. difficile infec-
tions, and the other two cases were refractory C. difficile infec-
tions. Two cases used EGD and infused stool via the biopsy 
channel of EGD. The other two cases used enema. In all four 
cases, C. difficile infection resolved. Two patients had adverse 
events. One patient who received EGD experienced vomiting, 
and another patient who received enema had mild diarrhea 
after fecal transplantation. In our case, we used a nasogastric 
tube placed in the third portion of the duodenum by EGD to 
perform the fecal transplantation. The patient had no adverse 
events and recovered from C. difficile infection. 
Fecal transplantation can be performed using a nasogastric 
tube, nasoenteric tube, EGD, colonoscopy, flexible sigmoidos-
copy, or enema [12]. Two review studies compared fecal 
transplantation outcomes based on the route of administra-
tion of donor feces. One systematic review reported that fecal 
transplantation by EGD or nasoenteric tube had a lower reso-
lution rate than that by colonoscopy and enema (76.4% vs > 
88.7%). Most patients received treatment or preparation be-
fore fecal transplantation; therefore, estimating the effect of 
fecal transplantation alone was difficult [15]. The other review 
study compared colonoscopic fecal transplantation with na-
sogastric fecal transplantation from 12 published studies. 
Colonoscopic fecal transplantation had a superior resolution 
rate (93.2%) compared with nasogastric fecal transplantation 
(85.3%), but the difference was statistically nonsignificant [16]. 
There has been no randomized, controlled trial comparing 
outcomes based upon the route of administration of fecal 
transplantation. Further investigation is required to determine 
which route of administration is best. 
Some adverse events were reported. Transient GI symptoms 
are common, including decreased bowel movement, abdomi-
nal cramping, increased bowel sounds and abdominal dis-
comfort. In fecal transplantation via the upper gastrointestinal 
tract, the risks of aspiration and vomiting should be consid-
ered. The colonoscopic approach could be dangerous in pa-
tients with severe colitis or colonic distension [12]. A random-
ized controlled study by Els van Nood et al. reported acute 
adverse events including diarrhea (94%), cramping (31%) and 
belching (19%) in nasoenteric infusion, but these symptoms 
improved within 3 hours [7]. Long-term adverse events are 
not well known and require further investigation [8]. 
This case had one major limitation. Generally, oral vanco-
mycin is stopped before fecal transplantation; however, oral 
vancomycin was continued and tapered in our case due to 
concerns regarding the potential failure of fecal transplanta-
tion. This could make it difficult to estimate the effect of fecal 
transplantation alone. Nevertheless, we are confident that fe-
cal transplantation resulted in the resolution of C. diffcile in-
fection because the patient exhibited no improvement during 
the previous 14 days of oral vancomycin therapy, but recov-
ered dramatically after fecal transplantation.
In conclusion, fecal transplantation could be a viable treat-
ment option not only for recurrent C. difficile infection, but 
also for severe initial infection. Further investigation is re-
quired to establish the optimal method of fecal transplanta-
tion and to ensure long-term safety.
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